Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Seyed-Mohammad Reza HashemianRasoul AliannejadMorteza ZarrabiMasoud SoleimaniMassoud VosoughSeyedeh-Esmat HosseiniHamed HossieniSaeid Heidari KeshelZeinab NaderpourEnsiyeh Hajizadeh-SaffarElham ShajarehHamidreza JamaatiMina Soufi-ZomorrodNaghmeh KhavandgarHediyeh AlemiAliasghar KarimiNeda PakNegin Hossieni RouzbahaniMasoumeh NouriMajid SorouriLadan KashaniHoda MadaniNasser AghdamiMohammad VaseiHossein BaharvandPublished in: Stem cell research & therapy (2021)
We suggest that multiple infusions of high dose allogeneic prenatal MSCs are safe and can rapidly improve respiratory distress and reduce inflammatory biomarkers in some critically ill COVID-19-induced ARDS cases. Patients that develop sepsis or multi-organ failure may not be good candidates for stem cell therapy. Large randomized multicenter clinical trials are needed to discern the exact therapeutic potentials of MSC in COVID-19-induced ARDS.
Keyphrases
- mesenchymal stem cells
- coronavirus disease
- cell therapy
- sars cov
- end stage renal disease
- clinical trial
- ejection fraction
- newly diagnosed
- acute respiratory distress syndrome
- high dose
- chronic kidney disease
- high glucose
- diabetic rats
- pregnant women
- extracorporeal membrane oxygenation
- prognostic factors
- oxidative stress
- low dose
- bone marrow
- intensive care unit
- acute kidney injury
- gene expression
- open label
- patient reported outcomes
- endothelial cells
- cross sectional
- density functional theory
- placebo controlled